International Journal of
INTELLIGENT SYSTEMS AND APPLICATIONS IN ENGINEERING
IJISAE
ISSN:2147-6799 www.ijisae.org Original Research Paper

Targeted Cancer Therapy Employing the Combination of Artificial Intelligence and Nanotechnology

[1]Abhishek Roy, [2]Prem Colaco, [3]Aseem Aneja, [4]Dr. Trapty Agarwal, [5]Ramkumar Krishnamoorthy

Submitted: 09/01/2024 **Revised**: 15/02/2024 **Accepted**: 23/02/2024

Abstract: Cancer is a deadly illness that accounts for about 10 million deaths annually around the globe. Different molecular fingerprints in the human body mean different prognostic information for cancer patients. However, variation in gene expression emerges as a result of different types of cancer and modifications in the cancers, complicating both diagnosis and treatment. Precision medicine in cancer therapy relies heavily on targeted drug delivery, which helps provide medicines to patients by strategically raising local concentrations of the substance there. Nanoparticle (NPs) mediated administering medications and the inclusion of Artificial Intelligence (AI) is helpful techniques for enhancing customized delivery systems for drugs with biomarker identification. The accumulation of NPs in localized cancer facilitates biomarker detection and allows for precise medication delivery planning. Using NPs for cancer targeting in conjunction with AI may lead to the development of cutting-edge systems for better categorizing and understanding the many forms of the illness. The evaluation of pharmacological effectiveness, the prediction of potential NPs interactions of the targeted medicine, and the discovery of biomarkers are all areas where cutting-edge AI systems may aid. Despite the obvious benefits of combining NPs with AI for targeted medication delivery, this topic has received surprisingly little attention in the literature, with most suggested studies focused instead on the intersection of AI and drug development. The primary objective of this research was to emphasize the impact of NPs' recent advances in drug administration on customized cancer treatment plans. Additionally, the paper emphasizes how combining AI and NPs might assist overcome some of the current difficulties in medication administration via a collaborative investigation.

Keywords: *Cancer therapy, biomarker, nanoparticles (NPs), drug delivery, artificial intelligence (AI)*

1. Introduction

The goal of targeted cancer treatment is to selectively attack cancer cells while causing as little damage to healthy cells as possible. In this approach, medications or therapies are used to attack just the biochemical pathways or genetic abnormalities that cancer cells have in common [1]. Using numerous medications or treatment modalities simultaneously to increase efficacy and circumvent resistance mechanisms is known as combination therapy in cancer treatment. Researchers and physicians are hoping that by combining diverse targeted medicines, they might obtain synergistic effects and better patient outcomes [2]. Many different targeted therapy combinations have been investigated and put into practice for the treatment of cancer. The molecular profile and genetic alterations of the tumor should guide the selection of a combination treatment [3]. Healthcare, materials science, electronics, and energy are just a few of the many areas that stand to benefit greatly from the marriage of AI with nanotechnology [4]. AI can scan massive volumes of data, speeding up the search for promising new drugs.

AI algorithms that assess patient data may help drive the engineering of NPs to transport pharmaceuticals to particular places inside the body, to optimize drug delivery and minimize adverse effects [5]. Data collected by nanosensors, tiny devices that can detect particular chemicals or biological markers, may be analyzed by AI. With these two factors together, we may be able to create diagnostic tools with unprecedented sensitivity and specificity. The data from nanosensors may be interpreted in real time by AI algorithms, allowing for accurate and quick diagnostics of cancer, infectious illnesses, and environmental contaminants [6]. When AI and nanotechnology are combined, precision medicine may be improved. AI systems that assess patient data, genetic information, and biomarkers may direct NPs engineering to target just sick cells. With this synergy, patients may get more effective care based on their individualized treatment regimens [7]. Micro and nanoscale robotic systems are now feasible because of advancements in nanotechnology. With the use of AI, these nanorobots may be instructed to carry out precise operations including medication distribution to specific areas, tissue healing, and minimally invasive surgery. Using AI algorithms, these nanorobots can more

[1]*Vivekananda Global University, Jaipur abhishek.roy@vgu.ac.in, Orcid Id- 000-0003-3972-7971*
[2]*Department of ISME, ATLAS SkillTech University, Mumbai, Maharashtra, India, Email Id- prem.colaco@atlasuniversity.edu.in, Orcid Id- 0009-0007-6319-3355*
[3]*Chitkara University, Rajpura, Punjab, India, aseem.aneja.orp@chitkara.edu.in, https://orcid.org/0009-0009-5607-1688*
[4]*Maharishi University of Information Technology, Lucknow, India - 226036, Email Id- trapty@muit.in, Orcid Id- 0009-0007-4081-4999*
[5]*Jain (Deemed to be University), Bangalore, Karnataka, India, Email Id- ramkumar.k@jainuniversity.ac.in, Orcid Id- 0000-0003-1164-6504*

effectively and safely explore the body, make choices in real-time, and adapt to new and changing surroundings [8]. AI algorithms may improve the development, production, and characterization of non-materials. Researchers in nanotechnology can speed up the creation of innovative materials with the necessary qualities by using AI's capacity to handle vast datasets and simulate complicated systems. Improvements in electronics, energy storage, and catalysis, among other areas, are possible as a result [9]. NPs may be modified to deliver chemotherapy medications to the location of a tumor rather than the healthy tissue around it. NPs with improved medication delivery may be designed using AI algorithms that assess patient data such as genetic information, imaging data, and tumor features. AI may aid in determining the optimal NPs size, surface characteristics, and drug release kinetics for patient-specific therapies [10]. Nanosensors can detect cancer biomarkers with pinpoint accuracy. AI systems may examine the information gathered by these nanosensors, looking for signs and patterns that indicate the presence or advancement of cancer. This may help with cancer screenings and keeping tabs on the disease over time, both of which can lead to more effective therapy [11]. AI may examine patient data, including genetic information, medical history, and treatment results, to create personalized prediction models. These models may be used to forecast the most productive combination therapy by simulating the reaction of cancer cells to such medications [12]. Incorporating AI with nanotechnology will allow for immediate feedback on the effectiveness of therapy. Transmitting constant input on treatment effectiveness and tumor dynamics is possible thanks to nanosensors implanted into tumors or circulating in circulation. Using this information, AI systems may instantly change treatment plans, improving outcomes while also reducing the risk of drug resistance [13]. Combining AI with nanotechnology in cancer treatment has the potential to greatly improve the effectiveness of individual therapies. However, it should be noted that these methods are still evolving and need to be tested and refined. The successful translation of these technologies into clinical applications relies heavily on clinical trials and ongoing multidisciplinary cooperation [14].

2. Related Works

In the investigation, the researchers will probe and question the relationships between gold nanotechnology, AI, and mathematical modeling for future medical applications. The use of AI and mathematical modeling in medical biophysics has been making remarkable strides recently. The use of these methods enhances nanotechnology research [13]. The use of AI in the creation of goods based on nanotechnology has the potential to revolutionize the healthcare industry by making possible the capture and analysis of massive datasets and the customization of precision nanomedicines for the treatment of cancer [14]. Nanotechnology has gradually spread to new areas, proving its worth in improving cancer treatment via applications in chemotherapy, radiation, diagnostics, and imaging. To develop more effective cancer treatments, more precise early detection tools, more powerful imaging modalities, and more potent radiation adjuvants, nanomaterials provide a wealth of diversity, usefulness, and applicability [15]. The primary goal of the study is to characterize the most pressing obstacles to diagnosing and treating colorectal cancer. The single-cell perspective is also used to describe the diverse character of this malignancy. From in vitro investigations through in vivo studies and clinical trials, the most important works in the photo- and radiation-employing nanotechnology-based treatments for colorectal cancer are covered. Preliminary investigations demonstrated that the prospect of combining both treatments must be studied to increase treatment efficiency, despite the positive findings employing NPs as photo- and radio-sensitizers in the photo- and radiotherapy [16]. The study [17] presents an AI-based technique for predicting NPs uptake by cells in response to varying cancer stages to help overcome these obstacles. With study, they show for the first time that it is possible to categorize different types of cancer cells using a combination of a machine-learning (ML) algorithm with distinctive cellular uptake responses for unique cancer cell types. In particular, it investigates the role of immunology after surgery for avoiding tumor recurrence by changing the antigenic state of the initial tumor and capitalizing on the power of external immune systems [18]. The research paper summarizes the current state of nano-immune engineering for metastatic cancers, with an emphasis on the many different nano-immunotherapeutic techniques. To prohibit tumors from returning after surgery, the protected system is used to modify the immunological state of the primary tumor, mobilize immune cells from the periphery, and obstruct the formation of a pre-metastatic environment [19]. The field of ontological precision medicine now incorporates this idea. With the use of precision medicine, a framework may be established for the proposal of data collecting, therapies, healthcare modification, and practices tailored to each specific cancer patient. AI is currently being used in the design of nano-encapsulated pharmaceuticals to maximize their distinctive features and validate the biological interactions and chemical pathways inside the cellular system [20]. In the study, they provide a concise synopsis of the processes of drug resistance, compare and contrast the efficacy of photodynamic therapy (PDT) and selective photo thermotherapy (SPT), and outline the cutting-edge work being done to find solutions to these intractable issues by using PDT and SPT that are mediated at the nanoscale. The clinical translational promise of this combined treatment is also discussed [21].

3. Methodology

Our study employed the standard PRISMA approach to literary analysis to address the research topics given. Despite the expanding corpus of work covering fields including delivery of medicines, drug design, bionanotechnology, and NPs for targeted administration, very few studies have focused on the question that this paper seeks to resolve. Though a search may be narrowed down to include NPs-mediated drug delivery in addition to AI, there is not enough information in review papers to do any kind of comparative method. As a result, a narrative assessment is taken into consideration with the primary objective of determining the possibility of AI and its incorporation in the field of bionanotechnology, particularly for targeted drug delivery, the challenge that is currently present, and the ways that AI can assist in resolving some of the difficulties associated with NP-based targeted drug delivery and, consequently, improve drug efficacy. The research includes literature written during the recent decade. In general, the topic of bionanotechnology for the treatment of cancer and the delivery of drugs is discussed, and relevant references are checked to see how they relate to our investigation.

3.1. Using nanotechnology for targeted medication delivery and improved medical accuracy

Nanotechnology is an up-and-coming discipline that merges scientific research and technological innovation to create novel nanoscale materials with wide-ranging biomedical and industrial engineering applications. The superior surface-to-volume ratio of nanotechnology is a major benefit over the material in general. NPs have recently found usage in several fields, including sensing, actuation, agriculture, biological analysis, and medicine. Advanced medical solutions for medication administration, cancer detection, and tissue engineering have all been significantly aided by the work of NPs. The use of NPs for the efficient transport of recombinant proteins, nucleotides, and vaccines is well established. Because of their versatility and the simplicity through which they can be produced from a wide range of inorganic and organic substances, including amino acids, and lipids, Polymers include organic substances, and metals, and are composed of carbon nanotechnology, NPs of all types are being studied for their capacity in delivering medications and healthcare imaging applications for the detection and management of cancer. While NPs have been successfully employed for targeted medication delivery, each form of NP has its own set of pros and cons. Recent attempts have been made to investigate and improve the use of nanotechnology in medicine, and research based on NPs has contributed much to this progress. To this end, engineered NPs are being studied as a possible answer in the wake of recent efforts to improve drug delivery platforms. Bio-distribution, cellular targeting, and molecular transport to target organelles are all areas where they have been demonstrated to excel and overcome the limitations of conventional delivery systems. Drug-encapsulated cargos that are carried across mitochondria may be more stable and soluble if NPs are used. This will allow the drug to circulate in patients for a longer time, which will increase its effectiveness and safety. Although NPs have been studied extensively, their use in facilitating drug delivery to patients has been dismally low because researchers have neglected to take into account key anatomical, physiological, and pathological differences between animals and humans. Because of this research void, we still don't know too much about how the human body and nanomedicines work and how they behave. In addition, the efficacy of nanotechnology, especially in treating complicated illnesses such as cancer, is severely constrained by the diversity of patients. Due to this study, we know surprisingly little about the inner workings of the human body and the characteristics of nanomedicines. Furthermore, the variety of patients poses serious challenges to the use of nanotechnology, particularly in treating complex disorders like cancer. A few examples of diagnostic NPs being studied for the development of individual disease profiles include "polymer dots" (PDs), "gold nanoparticles" (AuNPs), and "quantum dots" (QDs). Combining these NPs with therapy in the nanotechnology sector, as seen in Fig.1, may develop personalized medicine while improving the therapy results for each particular patient.



Fig.1. Drug delivery using nanoparticles

3.2. Methods of delivering drugs specifically to cancer cells

A greater understanding of carcinogenic mechanisms, cell biology, and the tumor environment has led to substantial advances in cancer treatment. However, because of the complexity of cancer, there is still a substantial mortality rate associated with many forms of cancer. In this setting, the ability to accurately target the administration of anticancer medications is crucial for increasing patient survival rates. Cancer medications may have a greater pharmacological effect if they are released selectively at the location of the tumor, and drug targeting facilitates this process. NPs may be used for either active or passive targeting. A passive approach is more effective for locating NPs in the goal organ inside the cancerous growth microenvironment, but targeted efforts may reveal NPs absorption capabilities by cancer cells displayed in Fig.2. Examples of targeted cancer medications that allow for tailored therapy include monoclonal antibody microscopic drugs and immunotoxins. To counteract the side effects of standard chemotherapy, scientists have developed targeted cancer medicines that only affect the cancer cells and not the healthy tissue around them, such as the epithelium inside. In this context, the goal of targeted medicine administration is to limit cancer spread by limiting cell proliferation and death. In addition, targeted cancer medicines disrupt the protein interactions that lead to carcinogenesis rather than concentrating on molecular alterations. For drugs to have the desired impact on tumor tissues, the enhanced permeability and retention (EPR) effect must be taken into account. The EPR effect is a hallmark of cancer cells that has led to a major advance in the field of cancer treatment. Consequently, the EPR effect is now essential for the design and implementation of numerous drug delivery systems, including liposomes, protein-polymer conjugates macromolecule agents, molecular imaging, antibody therapy, and the discovery of anticancer drugs. However, there are significant disagreements concerning the effects of EPR when NPs are used. Since there is a pressing need to improve therapeutic efficacies, more research and development efforts must be directed toward creating tumor-specific delivery methods for anticancer medicines.



Fig.2. Targeted medication delivery through nanoparticles for cancer therapy

3.3. Current methods of administering anti-cancer drugs

The Food and Drug Administration (FDA) has been actively engaged in research on NP-based drug delivery systems for many years at this point. Successful breast cancer treatment Abraxane uses an NPs version of the drug paclitaxel that is encapsulated in albumin. However, synthetic polymers like "poly D, L-lactic-co glycolic acid" (PLGA) are widely used in modern drug delivery systems due to their ability to biodegrade and biological compatibility. With the aid of an egg phospholipids emulsifier, soybean oil, and water are combined to create intralipid, an emulsion injection authorized by the FDA. The difficulties of solubility, buffering, passive targeting, and stability were all overcome in this formulation. Nanodrug-based cancer treatment has a similar challenge from extensive absorption by the reticuloendothelial system, which reduces the drug's effect at the tumor site while simultaneously raising toxicity. Studies have shown that Intralipid increases bioavailability and decreases cytotoxicity in monocytic cells. Furthermore, it has been shown that combining Intralipid with Abraxane considerably slows cancer growth. In recent years, researchers have focused on polymer-based drug delivery systems to deliver drugs and guarantee the sustained, dosing release of anticancer medicines. Polymeric nanoparticles, which have favorable physiochemical characteristics and potentially enhance tumor localization thanks to developments in nanotechnology, are also being investigated as possible drug delivery methods for cancer therapies. Since 2016, many clinical investigations have shown that Vyexos increases medication effectiveness at lower doses than free drug delivery. It has also been shown that the Vyexos drug delivery system can effectively provide a synergistic ratio of daunorubicin and cytarabine for the treatment of cancer. As a consequence, drug release is accompanied by enhanced contact with the target cell. Myocet liposomal, made up of liposomal doxorubicin (non-PEGylated) and licensed by the European Medicines Agency (EMA), is also designed to treat metastases from breast cancer.

3.4. Aspects of Artificial Intelligence in Nanomedicines

Several of the more well-known branches of AI include image recognition and natural language processing (NLP). These developments may eventually make it possible for robots to replicate human intellect to complete a wide range of challenging tasks. Large and diverse datasets are used to teach machine learning and deep learning models how to predict, categorize, or detect patterns in new data. New developments in the subject, however, have led to a broad range of solutions for a wide variety of real-world situations, so it's not only confined to the tasks listed here. Statistics, calculation, intelligence, categorization, forecasting, and recognition of objects are all things that can be uncovered by AI systems. The pharmaceutical industry has benefited greatly from the use of AI in the areas of chemical identification, productivity enhancement, regulatory compliance monitoring, data transformation, and process scalability and optimization. Artificial intelligence technologies have been more important in recent years for nanotechnology research across several domains, including scanning probe microscopy, simulations, and noncompeting. There are several artificial intelligence methods, but one has been utilized to distinguish local activities from spectroscopic reactions: functional recognition. Artificial neural networks (ANNs) in particular have been shown to play an important role in this regard, streamlining the process and ensuring that only relevant factors are taken into consideration. Neural network topologies are optimal in such scenarios because they are multi-layered, with one layer connecting to the next and ultimately leading to predictions, classifications, or recognitions. Most research into molecular structures, fragments, topological indices, and descriptors, as well as research into physiochemical qualities, is conducted using the typical feed-forward neural network. Researchers in the pharmaceutical industry are looking at ANNs as a means of comprehending pre-formulations and properly forecasting drug behaviors for use in drug design and discovery.

3.5. Using AI to Improve Drug Development and Administration

The use of AI methods to address nanotechnology issues is a perennial topic of discussion. To efficiently estimate parameters, anticipate outcomes, and run simulations of whole systems at the nanoscale, AI methodologies are being applied to the core fields of nanosystem design, noncompeting, and nanoscale simulation. Because of the inherent instability of bioactive chemicals, which may significantly compromise pharmacokinetic qualities, improving drug delivery procedures is crucial for enhancing the medicine's physiochemical aspects. Recently, AI methods have been used to improve medication delivery by designing, characterizing, and manufacturing drug delivery nanosystems. In addition to accelerating drug development, finding different small-molecule functions, and accurately predicting their actions, this integrated strategy has proved crucial. Foreseeing the effectiveness of drug combinations based on drug synergies, for instance, is advocated using several AI-relevant approaches. To improve medication localization at the tumor site, AI-based optimization of combined drug delivery employing a variety of NPs is being investigated. Different individuals' genetic profiles, including numerous molecular abnormalities; provide unique challenges for oncologists when treating cancer. Medication administration for cancer patients takes into account a wide range of factors, from medication characteristics to biological variables. When combined with other patient data including genetics, metabolism, proteomics, histology, and previous treatments, the resultant massive datasets make it difficult to optimize therapy choices for specific individuals. Where AI has shown the most promise. Physicochemical features of the biological membranes that divide the numerous compartments in the human body contribute to the body's complexity. Consequently, these divided systems are often reduced in complexity when used for medication organization. Targeted drug delivery systems must account for a variety of factors, including the most effective dosing of the medication, to ensure that it passes through the body's defenses and reaches the desired location, symbolized by tissue or cell membranes in general. To determine how the drug's biological context interacts with the drug's molecular properties, an in-depth knowledge of the drug's biological context is required. As medication delivery systems combine a growing variety of diverse characteristics for computing, this data complicates predictive computation. With complicated inputs like medication interactions, phenotypic information, chemical interactions, and genetic data, AI has shown a lot of promise in pharmacokinetics assessments. It can make personalized drug administration possible by better understanding the biological interactions that involve membranes.

3.6. Identifying and analyzing patient biomarkers for more precise medication administration

Important data for risk assessments, prognosis, treatment response identification, illness diagnosis, and disease progression monitoring may all be gleaned from cancer biomarkers, which play a pivotal role in oncology. The National Cancer Institute reports that the biomarker patterns of individual cancer patients may provide light on the efficacy of various cancer treatments. Therefore, doctors may better serve their patients by acquiring biomarker data to determine the most effective cancer therapy options. Cancer patients may be better screened for treatment by identifying their unique molecular profile, which is based on biomarkers. Furthermore, these individuals may be categorized based on the stage of malignancy, with the tumor being either localized or metastatic. Biomarker testing has come a long way in recent years, allowing doctors to better match patients with the most effective cancer therapies. However, biomarker testing encompasses both single-biomarker and multi-biomarker/multigene tests. The Oncotype DX test is a common cancer biomarker test used to determine whether a patient will respond to chemotherapy by analyzing the activity of 21 genes associated with breast cancer. These prediction requirements are where combining prediction and classification AI models might provide the greatest improvements. However, when talking about drug delivery, particularly for cancer therapies, the most important thing to keep in mind is that the medications be delivered precisely so that they activate just at the tumor location in question, without causing any damage to the surrounding healthy tissues. Acquiring molecular profiles for each patient, however, allows for targeted cancer therapy. Biomarkers and other disease-related data might fall under this category. Therefore, genomic, proteomic, metabolomic, macrobiotic, and epigenomic data are integral components of illness profiles. Quantum dots, gold nanoparticles, and carbon nanotubes are just a few examples of nanomaterials used in biomarker applications for detection. Furthermore, these nanomaterials have allowed for the development of novel approaches to the collection of highly specific diagnostic data, which has the potential to improve both the speed and accuracy with which diseases are diagnosed and the specificity with which they are treated. NPs are a flexible option that has many uses in the biomedical industry, such as in radiation, medication delivery, and diagnostic tests. Additionally, innovative NP-based systems are being investigated for enhanced drug penetration and intra-body monitoring of cancer therapies, allowing for more effective cancer treatment at lower risk than standard methods.

3.7. Nanorobots and other clever AI systems for drug delivery

Over the last several years, medical researchers have concentrated on creating and implementing micro-robotics. Studies reveal the great promise of nanorobots, despite continuous challenges in material design, manufacture, availability, and biocompatibility. Recent research has highlighted the potential of mesoporous silica NPs loaded with distress enzymes and gold NPs as nanomotors. In vivo, imaging was facilitated by radio labeling these nanomotors. Amazing discoveries in engineering and bionanotechnology have led to progress in incorporating smart sensors, power supply, and artificial intelligence into nanorobots. The use of AI technologies to automate molecular production and direct the actions of nanorobots is also being explored. Nanorobots for precise medicine administration through efficient nano-communication might similarly benefit from AI-based modeling and simulation. Advanced new tools There is research into using DNA nanorobots for biosensing and medication delivery. However, artificial neural networks (ANNs) are considered crucial parts of these tiny machines due to the neural networks' enhanced prediction skills and increased efficacy when utilized for identifying tumor cells for the administration of targeted medications. Fuzzy logic is useful in calculating medicine doses for intracellular administration after the detection of a tumor, and although the influence of AI on nanorobots has been widely discussed, it is not the only method that is successful. For instance, the linear mapping necessary to determine the proper dosage for intracellular administration may be successfully provided by fuzzy models.

4. Result and Discussion

Cancer research has benefited greatly from the use of AI-based methods. The majority of published studies investigate various forms of vague intelligence. About 41% of research has utilized CNN to classify cancer, making it the AI model with the highest prevalence for cancer prediction. Both traditional neural networks (NN) and more advanced Deep Neural Networks (DNN) have seen widespread application in the research community. Ensemble learning methods (such as Forest Classifier weighted voting, Gradient Boosting Machines), and Support vector machines (SVM) are widely employed in the literature as alternatives to deep learning methodologies. Fig.3 and Table 1 displays the dispersion of published works that make use of AI-based prediction models.



Fig.3. AI-Based Prediction Models

Table 1. Numerical outcomes of prediction model

Prediction Models	***Percentage (%)***
CNN	41
NN	10
SVM	9
DNN	8
Ensemble	8
RNN	4
KNN	3
LR	3
Fuzzy	3
Others	11

The majority of the studies analyzed for this summary concerned methods for automatically diagnosing and predicting cancer. The human breast and kidney have been studied the most. Brain, colorectal, cervical, and prostate cancer prognoses have received the greatest attention from researchers, alongside breast and kidney cancers. Fig. 4 and Table 2 shows the breakdown of published studies by cancer location. Prediction model accuracy is very sensitive to the nature of the training data. The accuracy and precision of the classification results are very sensitive to the quality of the training data. The majority of MRI scans were utilized in the evaluated studies for this report. CT scan pictures are the second most prevalent kind of data utilized. Besides dermoscopy and mammography, the literature also made use of endoscopic and pathological images. Fig.5 and Table 3 emphasizes how different types of data were utilized to train the prediction model, highlighting the resulting dispersion of publications.



Fig.4. Cancer site-wise distribution of patient

Table 2. Numerical outcomes of cancer site

Cancer site	*Number of patient*
Brain	16
Breast	23
cervical	15
Colorectal	16
Kidney	18
Liver	15
Lung	14
Thyroid	12
Stomach	13
Skin	14
Other types	13



Fig.5. Distribution of papers based on the type of training data

Table 3. Numerical outcomes of training data

Training data	*Percentage (%)*
MRI	25
CT	23
Papsmear test	8
Mammographic	8
miRNA	4
polyoimages	2
Endoscopic	6
permoscopic	6
Pathological	3
others	15

4.1. AI and NPs may overcome cancer imaging difficulties

Comprehensive, disease-specific data is required for high-quality cancer imaging, which includes but is not limited to exams, image additional processing, and translation for clinical presentation and therapy preparation. To assess the success of treatment, detect adverse effects, and foresee the likelihood of recurrence, it is necessary to identify tumor entities and metastatic patterns and collect additional medical data from several imaging techniques. To better visualize medication distribution in real-time and understand the efficacy of medication in vivo, recent developments have concentrated on merging molecules with drug delivery. Researchers are attempting to create a theranostic probe with many uses for targeted medicine delivery to improve patient outcomes. Furthermore, molecular visualization reduces the volume of work, generates more accurate information to establish potential drugs with optimal target's particularity and pharmacology efficacy, and overcomes the difficulties associated with evaluating pharmacodynamics and information using traditional approaches. Evaluation of nanomedicine-based drug delivery systems requires medical imaging, although research in this area has been sporadic. By incorporating imaging into drug administration, scientists hope to learn more about drug pharmacokinetics, biodistribution, and accumulation at the tumor location of interest. Hydrodynamic diameters using fluorescence modes are computed by this program to characterize tagged particles. Characterizing and validating real-time monitoring of the NPs population is also made easier. Since fluctuating FDG uptakes often cause noise in diagnostic pictures, this strategy may aid improve diagnosis. Shown in Fig.6 for an illustration of how these findings, when combined with AI, might enhance molecular imaging for drug administration. The obtained data may be used by prediction models to help assess a disease's prediction, while patient genetic profiles might be generated and determined by a response in therapy and therapeutic synergy with the help of classification models. Since AI algorithms have already been shown to be capable of analyzing big datasets with complicated patterns, this may be used to improve cancer detection and therapy via the use of AI for biomarker imaging. AI can predict how nanoparticles will interact with the medication of choice, the tumor site, and cell membranes. This information can be used to improve the composition of nanotechnology for cancer treatment.



Fig.6. Biomarker sensing using artificial intelligence: a graphical illustration of a future possibility

5. Conclusion

Nanomedicines are a developing area where flexible drug carriers are being tested for their potential to improve localized medication delivery and increase tumor site specificity. In addition, the potential benefits of integrating monotherapies with hybrid methods of cancer therapy are constantly being assessed. Traditional medication development and delivery systems provide several obstacles that make these alternatives more difficult to implement. Understanding therapeutic synergies is important, but defining specific patient profiles based on their unique molecular fingerprints is now crucial for the future of successful targeted drug delivery. These are essential since the percentage of unsuccessful therapies and poor patient response remains high. Further clinical criteria are needed to reduce treatment failures and recurrence rates in cancer patients. In this setting, smart computational models can handle complicated data with ease and provide reliable outcomes. The ability to quantify clinical information, image-guided drug delivery, patient classification based on molecular signatures, insight into treatment response, and quantification of clinical information are all dependent on AI's demonstrated capabilities with clinical imaging. AI for tailored drug administration has gotten relatively not much focus despite several attempts in the pharmaceuticals and nanomaterials areas. The findings of this research will provide light on how the efficiency of nanoparticle-based treatments may be increased via the use of artificial intelligence (AI) with images of NPs, personalized targeting, and the identification of cancer biomarkers [22]. Taking important insights from the research, subsequent endeavors may result in the development of intelligent solutions for the detection of biomarkers and systems for the tracking and analysis of nanoparticles.

Reference

[1] Wilson B, Km G. Artificial intelligence and related technologies enabled nanomedicine for advanced cancer treatment. Nanomedicine. 2020 Feb;15(05):433-5.

[2] Adir O, Poley M, Chen G, Froim S, Krinsky N, Shklover J, Shainsky-Roitman J, Lammers T, Schroeder A. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Advanced Materials. 2020 Apr;32(13):1901989.

[3] Haleem A, Javaid M, Singh RP, Rab S, Suman R. Applications of Nanotechnology in Medical field. Global Health Journal. 2023 Feb 25.

[4] Liu D, Dai X, Ye L, Wang H, Qian H, Cheng H, Wang X. Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2023 Jan;15(1):e1838.

[5] Chen M, Zhou Y, Lang J, Li L, Zhang Y. Triboelectric nanogenerator and artificial intelligence to promote precision medicine for cancer. Nano Energy. 2022 Feb 1; 92:106783.

[6] Brar B, Ranjan K, Palria A, Kumar R, Ghosh M, Sihag S, Minakshi P. Nanotechnology in colorectal cancer for precision diagnosis and therapy. Frontiers in Nanotechnology. 2021 Sep 16; 3:699266.

[7] Lin Z, Chou WC, Cheng YH, He C, Monteiro-Riviere NA, Riviere JE. Predicting nanoparticle delivery to tumors using machine learning and artificial intelligence approaches. International Journal of Nanomedicine. 2022 Jan 1:1365-79.

[8] Pan S, Zhang Y, Natalia A, Lim CZ, Ho NR, Chowbay B, Loh TP, Tam JK, Shao H. Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy. Nature nanotechnology. 2021 Jun; 16(6):734-42.

[9] Gadag S, Sinha S, Nayak Y, Garg S, Nayak UY. Combination therapy and nanoparticulate systems: Smart approaches for the effective treatment of breast cancer. Pharmaceutics. 2020 Jun 8; 12(6):524.

[10] Zhang Y. Development of NPs and their application in cancer treatment. In Proceedings of the 2nd International Symposium on Artificial Intelligence for Medicine Sciences 2021 Oct 29 (pp. 236-240).

[11] Hu D, Pan M, Yu Y, Sun A, Shi K, Qu Y, Qian Z. Application of nanotechnology for enhancing photodynamic therapy via ameliorating, neglecting, or exploiting tumor hypoxia. View. 2020 Mar;1(1):e6.

[12] Moore JA, Chow JC. Recent progress and applications of gold nanotechnology in medical biophysics using artificial intelligence and mathematical modeling. Nano Express. 2021 Apr 7;2(2):022001.

[13] Tan P, Chen X, Zhang H, Wei Q, Luo K. Artificial Intelligence Aids in Development of Nanomedicines for Cancer Management. InSeminars in Cancer Biology 2023 Jan 20. Academic Press.

[14] Kemp JA, Kwon YJ. Cancer nanotechnology: current status and perspectives. Nano convergence. 2021 Nov 2;8(1):34.

[15] Freitas SC, Sanderson D, Caspani S, Magalhães R, Cortés-Llanos B, Granja A, Reis S, Belo JH, Azevedo J, Gómez-Gaviro MV, Sousa CT. New Frontiers in Colorectal Cancer Treatment Combining Nanotechnology with Photo-and Radiotherapy. Cancers. 2023 Jan; 15(2):383.

[16] Alafeef M, Srivastava I, Pan D. Machine learning for precision breast cancer diagnosis and prediction of the nanoparticle cellular internalization. ACS sensors. 2020 May 29;5(6):1689-98.

[17] Zhang P, Meng J, Li Y, Yang C, Hou Y, Tang W, McHugh KJ, Jing L. Nanotechnology-enhanced immunotherapy for metastatic cancer. The Innovation. 2021 Nov 28;2(4):100174.

[18] Chen M, Zhou Y, Lang J, Li L, Zhang Y. Triboelectric nanogenerator and artificial intelligence to promote precision medicine for cancer. Nano Energy. 2022 Feb 1; 92:106783.

[19] Tajunisa M, Sadath L, Nair RS. Nanotechnology and Artificial Intelligence for Precision Medicine in Oncology. InArtificial Intelligence 2021 Jul 28 (pp. 103-122). CRC Press.

[20] Javed Iqbal M, Quispe C, Javed Z, Sadia H, Qadri QR, Raza S, Salehi B, Cruz-Martins N, Abdulwanis Mohamed Z, Sani Jaafaru M, Abdull Razis AF. Nanotechnology-based strategies for berberine delivery system in cancer treatment: pulling strings to keep berberine in power. Frontiers in molecular biosciences. 2021 Jan 15; 7:624494.

[21] Murar M, Albertazzi L, Pujals S. Advanced optical imaging-guided nano theranostics towards personalized cancer drug delivery. Nanomaterials. 2022 Jan 26; 12(3):399.

[22] Jayanthi, R,. & Sunethra, B. (2022). Review on Quantum Computers in Machine Learning. Technoarete Transactions on Advances in Computer Applications (TTACA), 1 (1), 20-24.